Avoid common mistakes on your manuscript.
The discrepancy between 99mTc-MDP bone scintigraphy and 18F-FDG positron emission tomography in lung and prostate cancer is related to these radiotracers’ mechanisms of uptake and retention [1, 2].
Slide A shows increased osteoblastic activity (mainly) within bone metastases of prostate cancer on 99mTc-MDP bone scintigraphy. Slide B shows increased utilization of deoxyglucose within the primary tumour and the very aggressive metastatic lesions of lung cancer on 18F-FDG positron emission tomography.
References
O’Sullivan JM, Cook GJ. A review of the efficacy of bone scanning in prostate and breast cancer. Q J Nucl Med 2002; 46:152–159.
Fukuchi K, Yamaguchi M, Hayashida K, Ishida Y. Discrepancy between99mTc-HMDP bone scan and F-18 FDG positron emission tomographic images in a patient with small cell lung cancer. Clin Nucl Med 2003; 28:232–233.
Author information
Authors and Affiliations
Corresponding author
Additional information
Rights and permissions
About this article
Cite this article
Garcia, J.R., Simo, M., Perez, G. et al. 99mTc-MDP bone scintigraphy and 18F-FDG positron emission tomography in lung and prostate cancer patients: different affinity between lytic and sclerotic bone metastases. Eur J Nucl Med Mol Imaging 30, 1714 (2003). https://doi.org/10.1007/s00259-003-1370-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-003-1370-3